30 Jul 2025

We’re proud to share that we have successfully completed the 100th surgery in our ongoing U.S. Investigational Device Exemption (IDE) study of the Polymotion® Hip Resurfacing System.

Launched earlier this year, the study is designed to evaluate the safety and performance of our Polymotion® Hip Resurfacing system a metal-on-polyethylene hip resurfacing device aimed at providing a bone-conserving alternative for younger, and more active patients. By moving away from contemporary metal-on-metal bearings, we are working to expand access to resurfacing for a broader patient population, particularly for women and other patients historically excluded from these procedures.

To date, surgeries have been performed across nine clinical sites by a team of 13 world-renowned hip arthroplasty surgeons. The 100th procedure was conducted by Dr Stephen Raterman at Florida Medical Clinic Orlando Health.

“I am so proud to be part of a team of skilled and talented surgeons to bring a valuable technology to the market. Hitting the Century Mark is a great milestone on our journey” said Dr. Raterman.

Tim Band Chief Commercial Officer of JointMedica stated “It’s a privilege to witness the enthusiasm and dedication that our IDE study surgeon team have demonstrated in achieving this enrolment rate. It’s a true testament to the vision that Dr Sharat Kusuma, and the JointMedica team had even before the study began.”

As we continue enrolment and plan to open additional sites later this year, we are encouraged by the positive feedback from our investigators and early clinical outcomes. This milestone underscores our commitment to advancing hip preservation technology and improving patient care around the world.

To learn more about the study, visit: https://www.jointmedica.com/ide-study